Latest News and Press Releases

International Cannabis Accelerates with 73% Net Revenue Growth and 100% Increase in Cannabis Flower Sales Volume Year-Over-Year Canadian Adult-Use and Medical Cannabis Net Revenue Combined Increased...

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205...

60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 ...

Purisaki Deep Cleansing Foot Pads 2026 overview: 2-in-1 detox and vitamin patch claims, ingredient context, pricing, and what to verify first

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert...

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.

LipoJaro's "jello recipe gelatin trick" weight loss claims examined. Ingredient research, dosing gaps, and consumer verification checklist reviewed.

Survivopedia's Doctor's Book of Survival Home Remedies evaluated: 2026 consumer research report examining herbal remedy research context and drug shortage

AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on...